() () CEO Joey Wiley tells Proactive it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year.
Wiley says the biopharma company, which acquires, develops and commercializes novel treatments for rare diseases, generated revenue growth of 18.5% to US$182.6M for 2020 from its two products on the market, metreleptin as a supplement for people with leptin deficiency and lomitapide, for adults with a rare cholesterol disorder.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...
FOR OUR FULL DISCLAIMER CLICK HERE
